CMPI.org

In the News

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

10/17/2024 12:00 AM | STAT

White Paper: Expanding Access to Pneumonia Vaccines — A Vital Public Health Measure

10/08/2024 12:00 AM | CMPI

07/18/2024 12:00 AM | CMPI

Tort bar’s newest collateral damage: Preterm babies

07/02/2024 12:00 AM | The Washington Times

New CMPI Book: And Nothing But the Truth

06/11/2024 12:00 AM | CMPI

Product Failure Is Not Process Failure

03/21/2024 12:00 AM | RealClearHealth

The Future of U.S. Biopharmaceutical Innovation and Supply Chain Security Lies in the Abraham Accords Region

03/07/2024 12:00 AM | RealClearHealth

Sorry, but the ‘drugs from Canada’ don’t work

01/05/2024 12:00 AM | New York Post

Center for Medicine in the Public Interest Statement on ITC TRIPS Waiver Report

10/18/2023 12:00 AM | CMPI

When It Comes to FDA Communications

10/17/2023 12:00 AM | RealClearHealth

Drug shortages reaching record levels

09/19/2023 12:00 AM | Scripps News

Richard Bagger Joins CMPI Board of Directors

09/05/2023 12:00 AM | CMPI

Inflation Reduction Act’s Medicare drug price negotiation program is unconstitutional

06/14/2023 12:00 AM | The Washington Times

Reality-Based Healthcare Reform

06/13/2023 12:00 AM | FDLI

CMS comments on IRA Implementation

05/15/2023 12:00 AM | CMPI

Abortion ruling adds to growing GOP discontent with FDA

04/13/2023 12:00 AM | Axios

Texas abortion ruling's broader implications for FDA drug approval

04/10/2023 12:00 AM | CNBC

With 340B Ruling, Corrupt Hospitals Get What They Deserve

04/06/2023 12:00 AM | Townhall

CMPI Interview: Drugmaker Eli Lilly Caps Insulin Cost

03/02/2023 12:00 AM | Newsmax TV

New Report Demonstrates How Hospitals, Pharmacies & PBMs Exploit the Federal 340B Drug Program to the Harm of Disadvantaged Patients

09/09/2022 12:00 AM | CMPI

1
2
3
4
...
11
Next

RECENT NEWS

The coronavirus could help pharma reset its reputation in Washington

STAT
03/03/2020 12:00 AM

The coronavirus could help pharma reset its reputation in Washington

The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington.... Read more

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

STAT
10/17/2024 12:00 AM

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub... Read more

Tort bar’s newest collateral damage: Preterm babies

The Washington Times
07/02/2024 12:00 AM

Tort bar’s newest collateral damage: Preterm babies

Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers... Read more

Read all News